Xenon Pharmaceuticals (XENE) Schedules Webcast for October 4th, 7AM EST to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

Go back to Xenon Pharmaceuticals (XENE) Schedules Webcast for October 4th, 7AM EST to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

October 3, 2021 4:32 PM EDT

BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b X-TOLE clinical trial on Monday, October 4, 2021 at... More